Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.

MLA

Cappuzzo, Federico, et al. “Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation with HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 21, no. 14, July 2003, pp. 2658–63. EBSCOhost, https://doi.org/10.1200/JCO.2003.01.039.

APA

Cappuzzo, F., Gregorc, V., Rossi, E., Cancellieri, A., Magrini, E., Paties, C. T., Ceresoli, G., Lombardo, L., Bartolini, S., Calandri, C., de Rosa, M., Villa, E., & Crino, L. (2003). Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 21(14), 2658–2663. https://doi.org/10.1200/JCO.2003.01.039

Chicago

Cappuzzo, Federico, Vanesa Gregorc, Elisa Rossi, Alessandra Cancellieri, Elisabetta Magrini, Carlo Terenzio Paties, Giovanni Ceresoli, et al. 2003. “Gefitinib in Pretreated Non-Small-Cell Lung Cancer (NSCLC): Analysis of Efficacy and Correlation with HER2 and Epidermal Growth Factor Receptor Expression in Locally Advanced or Metastatic NSCLC.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 21 (14): 2658–63. doi:10.1200/JCO.2003.01.039.